Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002374249 | SCV002686783 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-09-20 | criteria provided, single submitter | clinical testing | The p.E318* pathogenic mutation (also known as c.952G>T), located in coding exon 6 of the MSH2 gene, results from a G to T substitution at nucleotide position 952. This changes the amino acid from a glutamic acid to a stop codon within coding exon 6. This variant has been reported in an individual with MSI-H colorectal cancer that exhibited loss of MSH2 protein on immunohistochemistry (Kovac M et al. Fam Cancer, 2011 Sep;10:605-16). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Centre for Mendelian Genomics, |
RCV002467459 | SCV002762821 | pathogenic | Lynch syndrome 1 | 2022-12-09 | criteria provided, single submitter | research | PVS1, PS4_SUP, PM2_SUP |